The European Medicines Agency (EMA) has launched a new pilot program that gives some study leeway to drugmakers working on pediatric investigation plans (PIP) for innovative children’s medicines.

The European Medicines Agency (EMA) is requesting public comment on its new multi-stakeholder platform, Accelerating Clinical Trials (ACT) EU, for improving clinical trials within the trade bloc.